An Individualised and Patient-centred Follow-up Program for Women With Gynaecological Cancer (NEMO)
Primary Purpose
Empowerment, Cervical Cancer, Endometrial Cancer, Follow-up, Nurse-led, PROM
Status
Recruiting
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
NEMO: NEw MOdel of follow-up
Sponsored by
About this trial
This is an interventional supportive care trial for Empowerment, Cervical Cancer, Endometrial Cancer, Follow-up, Nurse-led, PROM
Eligibility Criteria
Inclusion Criteria:
- No adjuvant therapy after surgery
- Speak and write Danish
- Mentally capable to adapt to intervention
Exclusion Criteria:
- Indication for adjuvant therapy after primary surgical treatment
Sites / Locations
- Department of Gynecology, Odense University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Control
Intervention
Arm Description
Standard follow-up in doctors setting
Nurse-led follow-up with focus on empowerment and need assessment by use of ePROMS
Outcomes
Primary Outcome Measures
Patient Empowerment using the Health Education Impact Questionnaire (HEI-Q)
The primary outcome is measured as change of the skill and technique acquisition subscale score of the HEI-Q from baseline to 12 months post operative. Questionnaires are administered at 3 (baseline), 12, 24 and 36 months after surgery, respectively. Change from baseline to 24 and 36 months post operative are considered as secondary outcomes.
Secondary Outcome Measures
Patient Empowerment using the Health Education Impact Questionnaire (HEI-Q)
Change in other subscales of the HEI-Q from baseline to 12, 24 and 36 months post operative
Fear of cancer recurrence using the Fear of Cancer Recurrence Inventory (FCRI)
Change in fear of cancer recurrence from baseline to 12, 24 and 36 months respectively.
Health related quality of life using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Change in Global Health Status and other subscales of the C30 questionnaire from baseline to 12, 24 and 36 months respectively.
Cancer type specific quality of life using the EORTC Endometrial Cancer Module (EORTC QLQ-EN24)
Change from baseline to 12, 24 and 36 months respectively.
Cancer type specific quality of life using the EORTC Cervical Cancer Module (EORTC QLQ-CX24)
Change from baseline to 12, 24 and 36 months respectively.
Health Status using the EuroQol five-Dimensional (EQ5D) measure
Change from baseline to 12, 24 and 36 months respectively.
Full Information
NCT ID
NCT03838861
First Posted
February 6, 2019
Last Updated
April 21, 2022
Sponsor
University of Southern Denmark
Collaborators
Region of Southern Denmark, Danish Cancer Society
1. Study Identification
Unique Protocol Identification Number
NCT03838861
Brief Title
An Individualised and Patient-centred Follow-up Program for Women With Gynaecological Cancer
Acronym
NEMO
Official Title
A Randomised Clinical Trial Testing the Effect of an Individualised and Patient-centred Follow-up Program for Women With Gynaecological Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 1, 2019 (Actual)
Primary Completion Date
December 31, 2022 (Anticipated)
Study Completion Date
January 28, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Southern Denmark
Collaborators
Region of Southern Denmark, Danish Cancer Society
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This randomized controlled trial is testing the hypothesis that an individually focused and need-based nurse led follow-up program supported by electronic Patient Reported Outcome Measures for women with gynecological cancer will improve patient's empowerment, quality of life and involvement in the follow-up process besides reducing the patient's fear of cancer recurrence and degree of psychological distress, compared with a doctor led follow-up program. Further, nurse led follow-up by telephone, may reduce resources of the department as well as of the patients.
Detailed Description
Background The 2015 release of a new "Follow-up Program for Gynecological Cancers" by the Danish Health Authority (DHA) marked a break with traditional follow-up. The conclusion, derived from a Health Technology Assessment report from 2009 assessing the value of follow up in patients with endometrial and ovarian cancer, was, that regular follow-up visits do not improve survival and may consume unnecessary resources from both patients and health care personnel. As a consequence, a need based program was proposed where the follow-up is planned individually and adjusted according to patient's needs, risks and resources. It was further emphasized that patient's self-care ability should be supported and that access to specialist assessment should be easy available.
The new follow-up program was soon implemented in most national gynecological centers without previous evaluation in a pilot setting and with sparse evidence of benefits and harms. Further, as the recommendations from the DHA were broad, various forms of the model were introduced. Optimally, a national common professional agreement to standardize this transformation should be made. However, there is neither consistency nor sufficient knowledge about the optimal organizational follow-up model for gynecological cancer patients for this to be accomplished.
Internationally, various follow-up models for patients with cancer have been tested over the past decade. In the gynecological setting, evidence of the most optimal organization of follow-up is sparse. In general, studies suggest that follow-up conducted in a nurse or general practitioner setting demonstrate similar survival and recurrence detection rates and similar or slightly better rates of satisfaction and quality of life as compared to follow-up in a conventional setting.
From previous national studies on survivorship in Danish cancer patients it was learned learned that involvement of the general practitioners (GPs) in the follow-up process was not superior, and one in ten cancer patient was not satisfied with the contribution from their GP during the follow-up. Further, studies have shown that socioeconomic status had a significant impact on participation in rehabilitation activities of gynecological cancer patients with cervical and ovarian cancer patients being especially vulnerable. Unmet needs after cancer was found to be significantly associated with lower quality of life emphasizing the importance of need assessment. Preliminary data from a local randomized trial of follow up vs. no follow up in low risk endometrial cancer patients indicate that women report a higher degree of fear of recurrence after cancer treatment if they receive no follow-up as compared to a group receiving conventional follow-up. Hence, results obtained from prior studies on survivorship following gynecological cancer treatment indicate that follow-up to some extent seems needed and emphasize a need to develop new programs that facilitates self-management but at the same time embrace those most vulnerable. Question is how the patients needs are best accommodated with limited resources available. Comprehensive evaluation of effects, benefits and harms are essential before implementation of new initiatives.
This randomized study suggests a strong focus on promotion of cancer patients' self-care ability, in this study conceptualized as empowerment. Empowerment has been described as "a process by which people, organizations, and communities gain mastery over their affairs" and empowerment processes as "processes in which attempts to gain control, obtain needed resources, and critically understand one's social environment are fundamental. The process is empowering if it helps people to develop skills so that they can become independent problem-solvers and decision-makers". Focus on improvement of patient empowerment may thus unify the need for patient involvement, promotion of self-care ability and re-allocate resources to those patients most vulnerable who are often neglected in the follow-up process. Further, by empowering patients to master the consequences of their cancer disease, they may have fewer unmet needs, which may altogether improve quality of life and reduce fear of recurrence.
Use of electronic Patient Reported Outcome Measures (ePROMs) in the follow-up process has in selected populations shown to improve quality of life, reduce emergency room visits and hospitalizations, and improve quality-adjusted survival. Therefore ePROMs are suggested as important elements of future follow-up programs for cancer patients.
By combining nurse-led, needs based and individually planned follow-up, support of patient empowerment to self-manage with use of ePROMS to provide a safe and efficient follow-up program, the extended model of follow-up of the present study may improve patient outcomes and reduce economic as well as human resourses.
Study design Randomized, controlled study. Patients and health care professionals are not blinded, but randomization will be carried out centrally and the allocation sequence is computer-generated with varying block size and is kept unknown for all investigators. In addition, the patient's randomization status will be blinded during data processing and analysis.
The study will be developed, implemented and results will be published in accordance with the CONSORT statement.
Participants and Setting Women with cervical or endometrial cancer who are surgically treated at the Department of Gynecology at Odense University Hospital (OUH) are invited to participate. Women referred to oncological treatment post operative, who do not speak or read Danish, or where consent is unethical, i.e. caused by dementia, are not eligible. Patients will be recruited from 2019-2021.
The project is carried out by project nurses and doctors of the Department of Gynecology at OUH, where inclusion of patients and follow-up are conducted. The department operates 350-400 gynecological cancer patients annually, of which 50-70 with cervical cancer and 160-180 with endometrial cancer. Overall, about 60% (126-150 patients per year) will meet the inclusion criteria.
Patients, who do not wish to participate or for other reasons are not included, are referred to the doctor led follow-up program, which was implemented as the new standard during the autumn of 2017.
The project group consists of clinicians and researchers from the Department of Gynecology at OUH and Clinical Institute, Research Unit for General Practice, and Department of Psychology at University of Southern Denmark. In addition, patient representatives from the Danish "Patient Association of Women with Gynecological Cancer" are invited to give feedback on the proposed intervention, the questionnaires and all patient materials. In addition they will be asked to participate in the interpretation of the study results.
Odense Patient data Explorative Network (OPEN) which is a non-profit research infrastructure of OUH and University of Southern Denmark, contribute to the management of the questionnaires and data collection by using the Research Electronic Data Capture (REDCap) technology. Further, OPEN provides data management assistance and statistical support.
Study plan In the present study an innovative model is tested where specialized nurses handle the follow-up of endometrial and cervical cancer patients in the intervention group. The model is based on telephone consultations and developed to ensure timely identification of alarm symptoms and potential needs and support of the patient's empowerment to manage life after cancer.
Until the intervention baseline at 4 months post operative, all patients receive the same follow-up. Hence, before randomization, all patients are offered a follow-up consultation with a nurse 4 weeks post operative, where a need assessment is conducted using the "Preparatory Form for the patient" as described by the Region of Southern Denmark in their "Guide to need assessment of patients with cancer". Further, a disease specific list of alarm symptoms prepared by working groups of the Danish Gynecological Cancer Group (DGCG) is reviewed with the patient. The patient is carefully instructed to be aware of and contact the department in case of symptoms from the list as they may indicate recurrence, and that access to clinical examination is available and provided when needed.
All patients are eventually offered a follow-up consultation with a doctor 4 months post operative, where a clinical assessment is performed and the Preparatory Form and symptom list are reviewed as part of the needs assessment. If the patient meets the inclusion criteria, she is asked to participate in the study and is randomized if consent is obtained. The randomization status is immediately revealed. For control group patients a new appointment with the doctor is arranged if needed, and for patients in the intervention group a telephone follow-up with the attending nurse is arranged.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Empowerment, Cervical Cancer, Endometrial Cancer, Follow-up, Nurse-led, PROM
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Control
Arm Type
Active Comparator
Arm Description
Standard follow-up in doctors setting
Arm Title
Intervention
Arm Type
Experimental
Arm Description
Nurse-led follow-up with focus on empowerment and need assessment by use of ePROMS
Intervention Type
Behavioral
Intervention Name(s)
NEMO: NEw MOdel of follow-up
Intervention Description
The nurse led model is built upon phone contacts with content and intervals individually planned by the nurse and the patient. The individual contacts will be supported by graphic visualisation of ePROMs in REDCap filled out by the patient before each contact including DGCG's disease specific symptom list and the generic European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (24) supplemented with the relevant disease-specific add-on module (25, 26). The sum scores are visualised with colours to indicate severe problems (red), no problems (green) and mild or moderate problems (yellow and orange), respectively. Hence, alarm symptoms and problem areas are clearly presented to the project nurse and changes can be visualised over time enhancing the interpretation. The patient will be given access to own scoring results to obtain an understanding of the meaning of changes in health status.
Primary Outcome Measure Information:
Title
Patient Empowerment using the Health Education Impact Questionnaire (HEI-Q)
Description
The primary outcome is measured as change of the skill and technique acquisition subscale score of the HEI-Q from baseline to 12 months post operative. Questionnaires are administered at 3 (baseline), 12, 24 and 36 months after surgery, respectively. Change from baseline to 24 and 36 months post operative are considered as secondary outcomes.
Time Frame
Change from baseline (3 months post operative) to 12 months post operative.
Secondary Outcome Measure Information:
Title
Patient Empowerment using the Health Education Impact Questionnaire (HEI-Q)
Description
Change in other subscales of the HEI-Q from baseline to 12, 24 and 36 months post operative
Time Frame
Questionnaires are administered at 3 (baseline), 12, 24 and 36 months after surgery, respectively
Title
Fear of cancer recurrence using the Fear of Cancer Recurrence Inventory (FCRI)
Description
Change in fear of cancer recurrence from baseline to 12, 24 and 36 months respectively.
Time Frame
Questionnaires are administered at 3 (baseline), 12, 24 and 36 months after surgery, respectively
Title
Health related quality of life using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Description
Change in Global Health Status and other subscales of the C30 questionnaire from baseline to 12, 24 and 36 months respectively.
Time Frame
Questionnaires are administered at 3 (baseline), 12, 24 and 36 months after surgery, respectively
Title
Cancer type specific quality of life using the EORTC Endometrial Cancer Module (EORTC QLQ-EN24)
Description
Change from baseline to 12, 24 and 36 months respectively.
Time Frame
Questionnaires are administered at 3 (baseline), 12, 24 and 36 months after surgery, respectively
Title
Cancer type specific quality of life using the EORTC Cervical Cancer Module (EORTC QLQ-CX24)
Description
Change from baseline to 12, 24 and 36 months respectively.
Time Frame
Questionnaires are administered at 3 (baseline), 12, 24 and 36 months after surgery, respectively
Title
Health Status using the EuroQol five-Dimensional (EQ5D) measure
Description
Change from baseline to 12, 24 and 36 months respectively.
Time Frame
Questionnaires are administered at 3 (baseline), 12, 24 and 36 months after surgery, respectively
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
Female genital cancer patients
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
No adjuvant therapy after surgery
Speak and write Danish
Mentally capable to adapt to intervention
Exclusion Criteria:
Indication for adjuvant therapy after primary surgical treatment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stinne Holm Bergholdt, PHD
Phone
+45 40849722
Ext
NN
Email
stinne.holm.bergholdt@rsyd.dk
Facility Information:
Facility Name
Department of Gynecology, Odense University Hospital
City
Odense
State/Province
Region Of Southern Denmark
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stinne Holm Bergholdt, PHD
Phone
+45 40849722
Ext
NN
Email
stinne.holm.bergholdt@rsyd.dk
12. IPD Sharing Statement
Learn more about this trial
An Individualised and Patient-centred Follow-up Program for Women With Gynaecological Cancer
We'll reach out to this number within 24 hrs